Piel, Sarah http://orcid.org/0000-0002-1779-3532
Ehinger, Johannes K.
Chamkha, Imen
Frostner, Eleonor Åsander
Sjövall, Fredrik
Elmér, Eskil
Hansson, Magnus J.
Funding for this research was provided by:
Swedish government project and salary funding for clinically oriented medical research (F 2014/354)
Regional research and development grants (170083)
The Crafoord Foundation (2017-0776)
The Royal Physiographic Society in Lund (20141112)
Article History
Received: 21 May 2018
Accepted: 9 July 2018
First Online: 1 August 2018
Ethics approval and consent to participate
: All protocols were approved by the regional ethics board of Lund University, Sweden (permit no. 2013/181). Venous blood from healthy volunteers was drawn according to clinical standard after written informed consent was acquired.
: Not applicable.
: S.P., J.K.E., I.C., E.Å.F., F.S., E.E., and M.J.H have, or have had, salary from and/or equity interest in NeuroVive Pharmaceutical AB, a company active in the field of mitochondrial medicine. S.P., J.K.E., E.E., and M.J.H have filed patent applications for the use of succinate prodrugs for treatment of lactic acidosis or drug-induced side-effects due to complex I-related impairment of mitochondrial oxidative phosphorylation (WO/2015/155238) and protected carboxylic acid-based metabolites for treatment of mitochondrial disorders (WO/2017/060400, WO/2017/060418, WO/2017/060422).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.